Treatment history, n (%) | PD-L1 TC ≥ 25% (n = 132a) | PD-L1 TC < 25% (n = 264a) | Total (N = 412) |
---|---|---|---|
Palliative surgical interventions | 44 (33.3) | 74 (28.0) | 123 (29.9) |
Radiotherapy | 43 (32.6) | 63 (23.9) | 113 (27.4) |
Chemoradiation therapy | 1 (0.8) | 0 (0.0) | 1 (0.2) |
Line of chemotherapy, n | 132 | 264 | 412 |
 1st | 69 (52.3) | 159 (60.2) | 238 (57.8) |
 2nd | 24 (18.2) | 55 (20.8) | 84 (20.4) |
  ≥ 3rd | 8 (6.1) | 28 (10.6) | 42 (10.2) |
Type of first-line chemotherapy, n | 77 | 177 | 266 |
 Cetuximab | 38 (49.4) | 91 (51.4) | 132 (49.6) |
 Cisplatin | 41 (53.2) | 71 (40.1) | 119 (44.7) |
 Carboplatin | 15 (19.5) | 64 (36.2) | 84 (31.6) |
 Paclitaxel | 10 (13.0) | 56 (31.6) | 67 (25.2) |
 Docetaxel | 18 (23.4) | 22 (12.4) | 43 (16.2) |
 5-Fluorouracil | 35 (45.5) | 56 (31.6) | 97 (36.5) |
Type of second-line chemotherapy | 25 | 60 | 90 |
 Cetuximab | 8 (32.0) | 21 (35.0) | 30 (33.3) |
 Cisplatin | 1 (4.0) | 4 (6.7) | 5 (5.6) |
 Carboplatin | 6 (24.0) | 13 (21.7) | 20 (22.2) |
 Paclitaxel | 5 (20.0) | 20 (33.3) | 25 (27.8) |
 Docetaxel | 7 (28.0) | 10 (16.7) | 18 (20.0) |
 5-Fluorouracil | 5 (20.0) | 5 (8.3) | 10 (11.1) |